UNSPSC 51284703: Cloxiqine or cloxyquin

This classification denotes an anti-infective agent with the molecular formula C9H6ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BPF36H1G6S, chemically known as 8-quinolinol, 5-chloro- but generally known as cloxiquine, which bears US NIH Compound Identifier 2817. European Medicines Agency schedules Cloxiquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06784MIG.

The term CLOXIQUINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). CLOXIQUINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cloxiqine or cloxyquin bears US NLM identifiers UMLS ID C0772059 and NCI Concept Code C61689. SMILES: C1=CC2=C(C=CC(=C2N=C1)O)CL.

UNSPSC 51284703 Cloxiqine or cloxyquin, a Commodity code, shows limited direct alignment with recent state and local procurement activity. The code nominally identifies a specific pharmaceutical ingredient, but the recent opportunities posted under this code primarily reflect purchases of broader medical supplies, pharmaceuticals, and naloxone-based products rather than cloxiqine specifically. Seminole County, Florida issued an IFB on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, while the City of Tampa's Fire Department Rescue Division solicited sealed bids for 169 line items of medical and emergency supplies including respiratory equipment and cardiac monitoring devices in an estimated $700,000 contract designated as a sheltered market opportunity for certified Small Local Business Enterprises. These procurements reflect state and local demand for emergency medical supplies and pharmaceutical products, though neither directly targets cloxiqine as a line item.

The code's recent activity spans Florida and Texas, with a secondary reference to Minnesota through the MMCAP cooperative purchasing vehicle. The Texas Health and Human Services Commission issued a Request for Information in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling early-stage market research rather than a formal competitive solicitation. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026. The mismatch between the code's nominal scope and the actual work being solicited suggests that cloxiqine procurement through state and local channels either sees minimal activity or is not being consistently tagged to this code in current opportunities.